Tiffany Patrick, MPH, MBA joined Amicus in 2024 and currently serves as Chief Patient Officer. A longtime patient advocacy professional with experience spanning rare disease and oncology, she brings more than 20 years of leadership in the biotechnology industry. Her career has been dedicated to advancing the role of the patient voice —from early research through launch and access—with a focus on innovation and impact. Her forward-thinking leadership earned her a place among PharmaVOICE’s Top 100 innovators in life sciences for 2011.
Before joining Amicus, Ms. Patrick held patient advocacy and other leadership roles in small- to mid-size biotechnology companies, led teams within medical communications agencies serving the life sciences industry, and operated a strategic consulting practice advising life science companies on patient engagement. She brings these diverse perspectives to her work with patient organizations around the world, helping to bridge scientific innovation with the lived experiences of patients and families.
Ms. Patrick serves as a Strategic Advisor for Global Programs at the Oxalosis and Hyperoxaluria Foundation and is a member of The Max Foundation’s Max Think Tank. She is active across the rare disease and oncology biopharmaceutical landscape, bridging advocacy, development, access, and innovation.
She holds a degree in History from American University, a Master of Public Health from Benedictine University, and a Master of Business Administration from the University of Massachusetts, Amherst.